NCT07435584 2026-02-27
EVER-RECODE
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
Clinical Trials
10 trialsNCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting
NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT01154335 2022-05-03
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00419159 2019-04-23
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
Novartis
Phase 2 Completed
NCT01139138 2017-11-06
PIE
The Queen Elizabeth Hospital
Phase 1/2 Completed
NCT01058655 2017-04-13
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00522665 2015-05-15
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT00390364 2014-10-08
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00478634 2012-11-02
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Novartis
Phase 1 Completed